LNA oligonucleotides and the treatment of cancer

Details for Australian Patent Application No. 2005304110 (hide)

Owner Santaris Pharma A/S

Inventors Hansen, Bo; Asklund, Marlene; Rosenbohm, Christoph; Wissenbach, Margit; Kjaerulff, Lene Sonderbye; Westergaard, Majken

Agent Cullen & Co

Pub. Number AU-B-2005304110

PCT Pub. Number WO2006/050732

Priority PA 2004 01728 09.11.04 DK; 60/626,561 09.11.04 US

Filing date 9 November 2005

Wipo publication date 18 May 2006

Acceptance publication date 11 June 2009

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 31/7088 (2006.01) - Compounds having three or more nucleosides or nucleotides

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

28 June 2007 PCT application entered the National Phase

  PCT publication WO2006/050732 Priority application(s): WO2006/050732

11 June 2009 Application Accepted

  Published as AU-B-2005304110

13 August 2009 Alteration of Name

  The name of the applicant has been altered to Santaris Pharma A/S; Enzon Pharmaceuticals, Inc. 2006

8 October 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005304112-Potent LNA oligonucleotides for the inhibition of HIF-1a expression

2005304107-Method of preventive treatment of allergy by mucosal administration of an allergy vaccine